Full year update on Pixium Vision's liquidity agreement with Gilbert Dupont Paris, January 11, 2017 - 06:00 pm CET - Under the liquidity agreement signed between Pixium Vision and Société de Bourse Gilbert Dupont, the following resources were listed in the liquidity account on December 31, 2016:

  • 28,386 Pixium Vision shares

    € 117,818.7

    It is specified that as of June 30, 2016, the following resources were listed in the liquidity account:

  • 11,945 Pixium Vision shares

€ 247,857.1

ABOUT PIXIUM VISION

Pixium Vision's Mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period.

The company is developing two bionic retinal implant systems. IRIS®II, the company first bionic system, obtained CE mark in July 2016. In parallel, Pixium Vision has recently completed the pre-clinical study phases for PRIMA, a sub-retinal miniaturized wireless photovoltaic implant platform, and is planning to initiate first-in-human trials.

Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.

For more information, please visit: www.pixium-vision.com;

And follow us on: @PixiumVision; www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision

Contacts

Pixium Vision is listed on Euronext (Compartiment C) in Paris. ISIN: FR0011950641; Mnemo: PIX

IRIS® is a trademark of Pixium-Vision SA

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision

Khalid Ishaque, CEO investors@pixium-vision.com

+33 1 76 21 47 68

MediaRelations : Newcap Media

Annie-Florence Loyer - afloyer@newcap.fr

+33 1 44 71 00 12 / +33 6 88 20 35 59

Daphné Boccara - dboccara@newcap.fr

+33 1 44 71 94 93

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).

Pixium Vision SA published this content on 17 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 January 2017 07:16:01 UTC.

Original documenthttp://www.pixium-vision.com/en/dl/635_1484637011_Pixium_Vision-LiquidityContrat-Gilbert_Dupont_FR.pdf

Public permalinkhttp://www.publicnow.com/view/939BE4DB83421FB030EB31274E8DA9AD6CC631B1